Although targeted therapies are emerging to combat non-small cell lung cancer (NSCLC), the principal type of lung cancer, they are currently limited to a small fraction of tumors with defined oncogenic alterations, and no specific treatment exists against tumors carrying activating mutations in the most frequently mutated proto-oncogene, KRAS.
Rare populations of variant small cell lung cancer cells could be isolated that had additional genetic alterations and no longer underwent irreversible proliferation arrest in response to Hsp90 inhibitors.
The remaining patients developed no neural or vascular alterations and no bronchial stump insufficiency during follow-up.
Only a few renal corpuscles had major ultrastructural and structural alterations and no change in serum creatinine or creatinine clearance was observed.
12– 14 Using Sanger sequencing, we analyzed this mutation in the cases with STX11 alterations, and no mutations were observed (data not shown).
The majority of liver-specific transcripts (Pan et al., 2013) (which roughly represent hepatocyte differentiation state) were strongly repressed in Yaphigh hepatocytes from CCl4-treated mice, whereas WT and Yaplow hepatocytes showed minimal alterations and no bias towards decreased expression.
The extensive genetic and epigenetic profiling of the primary rectal cancer and of the matched metastases demonstrated the absence of KRAS, NRAS, BRAF and PIK3CA mutations, a microsatellite stable phenotype; in addition, there were no TP53 alterations and no recurrent CNAs on chromosome 8.
Often the ultimate aim is to produce a virus that has the desired phenotypic change and no additional alterations in characteristics.
For instance, 60% of MRI signal alteration was detected in the liver, which has high levels of c-MET expression, whereas in the kidneys, only 30% signal alteration was detected, and no change was observed in the muscles.
